Coagulation Diagnostic Testing Markets

By Author: Bharat Book Bureau
Total Articles: 1486
Comment this article

Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the most important segments of the in vitro diagnostics market for the foreseeable future. Many of the new models of laboratory coagulation testing devices and reagents, which are dominated by prothrombin time (PT) and activated partial thromboplastin time (aPTT), will include upgrades such as greater automation and the integration of more esoteric coagulation tests such as D-dimer and antiphospholipid assays. This TriMark Publications report provides a comprehensive examination of the coagulation and antiplatelet testing market. It examines the available and emerging technologies being utilized by the coagulation and antiplatelet testing field and describes the current product lines of almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for coagulation and antiplatelet testing.

Moreover, the study defines the dollar volume of sales, both in the U.S. and worldwide, and analyzes the factors that influence the size and growth of the market. Each company is ...
... discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

Table of Contents
1. Overview 10
1.1 Statement of Report 10
1.2 About this Report 11
1.3 Scope of the Report 11
1.4 Objectives 12
1.5 Methodology 12
1.6 Executive Summary 13

2. Introduction to Hemostasis and Blood Coagulation 15
2.1 Vascular Constriction 15
2.2 Platelet Activation and Platelet Plug Formation 15
2.3 Blood Coagulation 16
2.3.1 Coagulation Cascade 16
2.3.2 Current Cell-Based Model for Blood Coagulation 17
2.3.2.1 Initiation of Blood Coagulation 17
2.3.2.2 Amplification of Blood Coagulation 18
2.3.2.3 Propagation of Blood Coagulation 19
2.4 Fibrinolysis 19
2.5 Regulation of Coagulation 20
2.5.1 Tissue Factor Pathway Inhibitor 20
2.5.2 Antithrombin 21
2.5.3 Thrombomodulin and Protein C 22
2.5.4 Protein Z and Protein Z-dependent Protease Inhibitor 22
2.5.5 Prostacyclin 22
2.6 Clinical Significance of Blood Coagulation and Anticoagulants 22
2.6.1 Overview of Bleeding Disorders 23
2.6.2 Overview of Hypercoagulable Disorders 24
2.6.3 Anticoagulation Therapy in Cardiovascular Disease 25
2.7 Overview of Commonly Used Drugs to Regulate Coagulation 27
2.7.1 Heparin (Unfractionated) 28
2.7.2 Low Molecular-Weight Heparin (LMWH) 28
2.7.3 Fondaparinux 29
2.7.4 Warfarin (Coumadin) 29
2.7.5 Direct Factor Xa Inhibitors 29
2.7.6 Direct Thrombin Inhibitors 30
2.7.7 Thrombolytic Agents 31
2.7.8 Antiplatelet Agents 31
2.7.9 Differences Between Antiplatelets and Anticoagulants 33
2.8 Situations Requiring Coagulation Testing 33
2.8.1 Managing Anticoagulation Therapies 33
2.8.1.1 Monitoring Unfrationated Heparin 34
2.8.2.2 Monitoring Low-Molecular Weight Heparin 36
2.8.1.3 Monitoring Warfarin 36
2.8.1.4 Monitoring Direct Factor Xa Inhibitors 38
2.8.1.5 Monitoring Direct Thrombin Inhibitors 38
2.8.1.6 Monitoring Antiplatelet Therapies 39
2.8.1.7 Perioperative Monitoring of Coagulation 41
2.8.1.8 Monitoring of Coagulation During Hemodialysis 41
2.8.2 Diagnosing and Managing Bleeding Disorders 42
For more information kindly visit :
http://www.bharatbook.com/healthcare-market-research-reports/coagulation-diagnostic-testing-markets.html
Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/